Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.
Lutris Pharma has raised $30.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2025.
Lutris Pharma's investors include Pontifax, Columbus Venture Partners, Peregrine Ventures, aMoon Fund, California Institute for Regenerative Medicine.
Lutris Pharma is headquartered in Tel Aviv-yafo, Israel.
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.
Lutris Pharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lutris Pharma — Funding & Investors." VCBacked, January 28, 2025, https://www.vcbacked.co/company/lutris-pharma. Accessed October 18, 2026.
VCBacked. (2025). Lutris Pharma — Funding & Investors. Retrieved October 18, 2026, from https://www.vcbacked.co/company/lutris-pharma
{{cite web |title=Lutris Pharma — Funding & Investors |url=https://www.vcbacked.co/company/lutris-pharma |website=VCBacked |access-date=October 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated